We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Prehospital Plasma GFAP Analyzed as Stroke Biomarker

By LabMedica International staff writers
Posted on 30 Sep 2021
Print article
Image:  Simoa HD-1 Analyzer is the latest model fully automated Simoa bead-based immunoassay platform (Photo courtesy of Quanterix)
Image: Simoa HD-1 Analyzer is the latest model fully automated Simoa bead-based immunoassay platform (Photo courtesy of Quanterix)
Emergency medical services (EMS) encountering patients with acute stroke symptoms are challenged with the difficult task of rapidly triaging the patient to the appropriate hospital with sufficient therapeutic capabilities.

Glial fibrillary acidic protein (GFAP) and tau are differentially released in ischemic and hemorrhagic stroke (HS), but their very early release dynamics are unknown, as previous studies have focused on single-time point measurements after hospital admission. Circulating GFAP was increased in only 36% of patients with intracerebral hemorrhage (ICH).

Clinical Neuroscientists at the Helsinki University Hospital (Helsinki, Finland) and their colleagues performed ultra-sensitivite single-molecule array measurements of plasma GFAP and total tau in a stroke code patient cohort with cardinal stroke symptoms. Sequential sampling included two ultra-early samples and a follow-up sample on the next morning. The team included 272 cases (203 acute cerebral ischemia [ACI], 60 HS, and nine stroke mimics).

The investigators performed plasma GFAP and total tau (T-tau) measurements using commercially available GFAP Discovery and Tau 2.0 kits on the Simoa HD-1 Analyzer, (Quanterix, Billerica, MA, USA). The median (IQR) last-known-well to sampling time was 53 (35–90) minutes for initial prehospital samples, 90 (67–130) minutes for secondary acute samples, and 21 (16–24) hours for next morning samples.

The scientists reported that the plasma GFAP was significantly higher in patients with HS than ACI (P < 0.001 for <1 hour and <3 hour prehospital samples, and <3 hour secondary samples), while total tau showed no intergroup difference. The prehospital GFAP release rate (pg/mL/minute) occurring between the two very early samples was significantly higher in patients with HS than ACI [2.4 (0.6–14.1)] versus 0.3 (0.3–0.9) pg/mL/minute. For cases with <3 hour prehospital sampling (ACI n = 178, HS n = 59), a combined rule (prehospital GFAP >410 pg/mL, or prehospital GFAP 90–410 pg/mL together with GFAP release >0.6 pg/mL/minute) enabled ruling out HS with high certainty (NPV 98.4%) in 68% of patients with ACI (sensitivity for HS 96.6%, specificity 68%, PPV 50%).

The authors concluded that their study demonstrated that when sufficiently sensitive assay technology is applied, the very early prehospital GFAP plasma concentration and its prehospital release rate can in combination provide improved differential diagnosis of patients with ACI and HS. GFAP ruled out HS in two-thirds of patients with ACI with high certainty, with improved performance in cases with moderate to severe stroke symptoms. The study was published on August 12, 2021 in the journal Clinical Chemistry.

Related Links:
Helsinki University Hospital
Quanterix


Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
New
ELISA Mini Workstation
Crocodile 5-in-one
New
SARS-CoV-2 Antigen Test
Actim SARS-CoV-2
New
Gold Supplier
Desktop Urine Analyzer
MONOZYME TX2000

Print article

Channels

Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.